No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In BCG-Naive Patients With High-Risk Non-Muscle-Invasive Bladder Cancer By Ogkologos - November 17, 2025 278 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ALBAN (GETUG-AFU 37) study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR The Recently Leaked Secret to Marijuana News Discovered April 28, 2023 Enfortumab Vedotin Plus Pembrolizumab Shows a High Confirmed Objective Response Rate... July 14, 2023 105-Year-Old Woman Sets Record For 100-Meter Dash November 16, 2021 Training Cancer Researchers: A Conversation with Dr. Oliver Bogler April 1, 2020 Load more HOT NEWS Stealing Strategies from Cancerous T Cells May Boost Immunotherapy Changes to chromosomes impact how children’s brain tumours respond to treatment Workout Wednesdays – Chest Exercises Part 2 Sacituzumab Govitecan Demonstrates Significant Improvement in PFS in Heavily Pretreated, Locally...
